Narrow your search

Library

ULiège (2)

KU Leuven (1)

Odisee (1)

Thomas More Kempen (1)

Thomas More Mechelen (1)

UCLL (1)

UGent (1)

ULB (1)

VIVES (1)


Resource type

book (2)


Language

English (2)


Year
From To Submit

2023 (2)

Listing 1 - 2 of 2
Sort by

Book
Commercializing successful biomedical technologies : basic principles for the development of drugs, diagnostics and devices
Author:
ISBN: 1009302337 1009302345 1108186696 Year: 2023 Publisher: Cambridge : Cambridge University Press,

Loading...
Export citation

Choose an application

Bookmark

Abstract

Transform your research into commercial biomedical products with this revised and updated second edition. Covering drugs, devices and diagnostics, this book provides a step-by-step introduction to the process of commercialization, and will allow you to create a realistic business plan to develop your ideas into approved biomedical technologies. This new edition includes: Over 25% new material, including practical tips on startup creation from experienced entrepreneurs. Tools for starting, growing and managing a new venture, including business planning and commercial strategy, pitching investors, and managing operations. Global real-world case studies, including emerging technologies such as regulated medical software and Artificial Intelligence (AI), offer insights into key challenges and help illustrate complex points. Tips and operational tools from established industry insiders, suitable for graduate students and new biomedical entrepreneurs.


Book
The Challenge of CMC Regulatory Compliance for Biopharmaceuticals
Author:
ISBN: 3031319095 3031319087 Year: 2023 Publisher: Cham : Springer Nature Switzerland : Imprint: Springer,

Loading...
Export citation

Choose an application

Bookmark

Abstract

Each year for the past three years, there have been about 50 new molecular medicines approved by the United States Food & Drug Administration (FDA), of which approximately 25% were new biopharmaceuticals. Over 200 recombinant proteins, monoclonal antibodies, antibody drug conjugates, fusion proteins, and Fab fragments are now in the marketplace in both the United States of America (USA) and European Union (EU). There are also now over 60 biosimilars available for all major classes of recombinant proteins and monoclonal antibodies. In addition, gene therapies using genetically engineered viruses and genetically engineered cells are now in the marketplace, and continually growing. This degree of change is reflected in the over 400 CMC regulatory compliance references listed in this book that were either issued or updated since the release of the third edition. Deficiencies in biopharmaceutical CMC regulatory compliance rarely result in termination of a product, but in can readily cause months if not years of delay in initiating clinical trials, or advancing clinical development stages, or even market approval. In summary, this book: Updates real-world CMC deficiency examples with current examples; Addresses current FDA and EMA requirements and expectations for CMC regulatory compliance; Now includes CMC regulatory compliance for the new gene-based biopharmaceuticals.

Listing 1 - 2 of 2
Sort by